Rapid Point-of-Care COVID-19 Antigen Test Based on Waveguide Technology Could Deliver Results in Under Six Minutes

The LightDeck antigen test will be a significantly faster alternative to the current PCR based diagnostic tests, and offer better sensitivity and specificity than the available lateral flow-based tests that require at least 15 minutes to deliver results.

LightDeck has been awarded a USD 5.65 million contract from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the US Department of Health and Human Services (HHS), to develop the rapid antigen test to detect SARS-CoV-2.

“The LightDeck COVID-19 Antigen Test will build on the existing product platform,” said Chris Myatt, CEO and Founder of LightDeck Diagnostics. “Every minute matters when we’re dealing with infectious diseases. We believe our technology can provide an optimal solution to the current gaps in COVID-19 diagnostic testing on a national level.”

Related Links:
LightDeck Diagnostics